Coronavirus Disease 2019 and Takotsubo Syndrome

TL;DR

This paper reviews the link between coronavirus disease 2019 (COVID-19) and Takotsubo syndrome, a heart condition, focusing on how they are connected and managed.

Contribution

The paper provides a comprehensive overview of TTS in the context of COVID-19, summarizing current understanding and treatment strategies.

Findings

Takotsubo syndrome is increasingly diagnosed in patients with COVID-19.

ACE2 receptors in the lungs and heart may play a role in the pathophysiology of TTS in these patients.

There is a lack of randomized studies on TTS related to COVID-19, leaving its mechanisms unclear.

Abstract

The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global public health
emergency. As the number of confirmed cases increases, cardiovascular
complications, such as myocardial injury and cardiac dysfunction, are evidenced.
Takotsubo syndrome (TTS), which is common in
the intensive care unit, is diagnosed among COVID-19 patients. There have been 68
more cases reports with over 119 patients since a COVID-19 patient with TTS was
first reported on April 14, 2020. Angiotensin-converting enzyme 2 (ACE2), which
is widely expressed in the lungs and heart, is the virus receptor. Nevertheless,
randomized studies on COVID-19 related TTS are lacking, and the pathogenesis and
pathophysiology are still
unclear. Therefore, this review provides an overview of the potential
pathogenesis, pathophysiology, clinical manifestations, diagnosis, and treatment
strategy for TTS in the COVID-19 era based on current practices.

Figures